CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trialPUBT·Jul 14 at 06:35 AMCRVO-0.37%
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)Unusual Whales·Jul 14 at 06:31 AMCRVO-0.37%
CervoMed completes enrollment in Phase 2a neflamapimod trial for nonfluent PPAPUBT·Jul 9 at 06:34 AMCRVO-0.37%
CervoMed to present new neflamapimod Phase 2 data in Lewy body dementia at AAIC 2026PUBT·Jul 6 at 06:33 AMCRVO-0.37%
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 | CRVO Stock NewsStockTitan·Jul 5 at 10:30 PMCRVO-0.37%
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesUnusual Whales·Jun 22 at 03:07 PMCRVO-0.37%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 22 at 07:05 AMCRVO-0.37%CDT-6.42%
CervoMed prices USD 10 million registered direct stock offering at USD 4 per sharePUBT·Jun 22 at 05:02 AMCRVO-0.37%
CervoMed climbs 4% during regular trading on patent approval, $10M offeringUS Stock Market Update·Jun 18 at 01:20 PMCRVO-0.37%
CervoMed Climbs 5% on USPTO Neflamapimod Patent Approval for DLBUS Stock Market Update·Jun 18 at 01:13 PMCRVO-0.37%
